Literature DB >> 8296317

Catalytic selectivity of human cytochrome P450 enzymes: relevance to drug metabolism and toxicity.

F P Guengerich1.   

Abstract

About 30 different human cytochrome P450 (P450) enzymes have now been characterized in considerable detail. It is possible to elucidate their catalytic specificities towards drugs, steroids, carcinogens, and other potential substrates with in vitro assays. It is also possible to ascertain the levels of individual P450 enzymes in humans with the use of drugs, after appropriate assay validation. The ability to discern catalytic selectivity and levels of P450 enzymes within individuals offers considerable potential in drug development, prevention of undesirable drug-drug interactions, and understanding the etiology of diseases resulting from exposure to potentially toxic and carcinogenic chemicals.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8296317     DOI： 10.1016/0378-4274(94)90156-2

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN： 0378-4274            Impact factor:   4.372


  19 in total

1.  CYP2E1 active site residues in substrate recognition sequence 5 identified by photoaffinity labeling and homology modeling.

Authors:  Samuel L Collom; Arvind P Jamakhandi; Alan J Tackett; Anna Radominska-Pandya; Grover P Miller
Journal:  Arch Biochem Biophys       Date:  2006-11-02       Impact factor: 4.013

Review 2.  Substrate binding to cytochromes P450.

Authors:  Emre M Isin; F Peter Guengerich
Journal:  Anal Bioanal Chem       Date:  2008-07-13       Impact factor: 4.142

Review 3.  Inhibition and induction of cytochrome P450 and the clinical implications.

Authors:  J H Lin; A Y Lu
Journal:  Clin Pharmacokinet       Date:  1998-11       Impact factor: 6.447

4.  Genome-wide association study identified SNP on 15q24 associated with bladder cancer risk in Japanese population.

Authors:  Koichi Matsuda; Atsushi Takahashi; Candace D Middlebrooks; Wataru Obara; Yasutomo Nasu; Keiji Inoue; Kenji Tamura; Ichiro Yamasaki; Yoshio Naya; Chizu Tanikawa; Ri Cui; Jonine D Figueroa; Debra T Silverman; Nathaniel Rothman; Mikio Namiki; Yoshihiko Tomita; Hiroyuki Nishiyama; Kenjiro Kohri; Takashi Deguchi; Masayuki Nakagawa; Masayoshi Yokoyama; Tsuneharu Miki; Hiromi Kumon; Tomoaki Fujioka; Ludmila Prokunina-Olsson; Michiaki Kubo; Yusuke Nakamura; Taro Shuin
Journal:  Hum Mol Genet       Date:  2014-10-03       Impact factor: 6.150

5.  Sex steroid hormones regulate constitutive expression of Cyp2e1 in female mouse liver.

Authors:  Maria Konstandi; Jie Cheng; Frank J Gonzalez
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-04-02       Impact factor: 4.310

6.  Fondaparinux sodium is not metabolised in mammalian liver fractions and does not inhibit cytochrome P450-mediated metabolism of concomitant drugs.

Authors:  Carolyne Lieu; Juan Shi; François Donat; Robert Van Horn; William Brian; John Newton; Leon Delbressine; Ria Vos
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 7.  The influence of age and sex on the clearance of cytochrome P450 3A substrates.

Authors:  Monette M Cotreau; Lisa L von Moltke; David J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

8.  Electrochemiluminescent arrays for cytochrome P450-activated genotoxicity screening. DNA damage from benzo[a]pyrene metabolites.

Authors:  Eli G Hvastkovs; Minjeong So; Sadagopan Krishnan; Besnik Bajrami; Maricar Tarun; Ingela Jansson; John B Schenkman; James F Rusling
Journal:  Anal Chem       Date:  2007-01-30       Impact factor: 6.986

Review 9.  Grapefruit juice-drug interactions.

Authors:  D G Bailey; J Malcolm; O Arnold; J D Spence
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

Review 10.  Ontogeny of hepatic and renal systemic clearance pathways in infants: part I.

Authors:  Jane Alcorn; Patrick J McNamara
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.